» Articles » PMID: 20686020

Recombinant Soluble, Multimeric HA and NA Exhibit Distinctive Types of Protection Against Pandemic Swine-origin 2009 A(H1N1) Influenza Virus Infection in Ferrets

Abstract

The emergence and subsequent swift and global spread of the swine-origin influenza virus A(H1N1) in 2009 once again emphasizes the strong need for effective vaccines that can be developed rapidly and applied safely. With this aim, we produced soluble, multimeric forms of the 2009 A(H1N1) HA (sHA(3)) and NA (sNA(4)) surface glycoproteins using a virus-free mammalian expression system and evaluated their efficacy as vaccines in ferrets. Immunization twice with 3.75-microg doses of these antigens elicited strong antibody responses, which were adjuvant dependent. Interestingly, coadministration of both antigens strongly enhanced the HA-specific but not the NA-specific responses. Distinct patterns of protection were observed upon challenge inoculation with the homologous H1N1 virus. Whereas vaccination with sHA(3) dramatically reduced virus replication (e.g., by lowering pulmonary titers by about 5 log(10) units), immunization with sNA(4) markedly decreased the clinical effects of infection, such as body weight loss and lung pathology. Clearly, optimal protection was achieved by the combination of the two antigens. Our observations demonstrate the great vaccine potential of multimeric HA and NA ectodomains, as these can be easily, rapidly, flexibly, and safely produced in high quantities. In particular, our study underscores the underrated importance of NA in influenza vaccination, which we found to profoundly and specifically contribute to protection by HA. Its inclusion in a vaccine is likely to reduce the HA dose required and to broaden the protective immunity.

Citing Articles

COBRA N2 NA vaccines induce protective immune responses against influenza viral infection.

Zhang X, Skarlupka A, Shi H, Ross T Hum Vaccin Immunother. 2024; 20(1):2403175.

PMID: 39291424 PMC: 11657087. DOI: 10.1080/21645515.2024.2403175.


Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge.

Pascha M, Ballegeer M, Roelofs M, Meuris L, Albulescu I, van Kuppeveld F NPJ Vaccines. 2024; 9(1):97.

PMID: 38821988 PMC: 11143307. DOI: 10.1038/s41541-024-00891-3.


Cross-protection against influenza viruses by chimeric M2e-H3 stalk protein or multi-subtype neuraminidase plus M2e virus-like particle vaccine in ferrets.

Kim K, Bhatnagar N, Subbiah J, Liu R, Pal S, Raha J Virology. 2024; 595:110097.

PMID: 38685171 PMC: 11110495. DOI: 10.1016/j.virol.2024.110097.


Anti-neuraminidase immunity in the combat against influenza.

Zhang X, Ross T Expert Rev Vaccines. 2024; 23(1):474-484.

PMID: 38632930 PMC: 11157429. DOI: 10.1080/14760584.2024.2343689.


Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines.

Moral-Sanchez I, Wee E, Xian Y, Lee W, Allen J, Torrents de la Pena A NPJ Vaccines. 2024; 9(1):74.

PMID: 38582771 PMC: 10998906. DOI: 10.1038/s41541-024-00862-8.


References
1.
Rimmelzwaan G, Baars M, Claas E, Osterhaus A . Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods. 1998; 74(1):57-66. DOI: 10.1016/s0166-0934(98)00071-8. View

2.
Harbury P, Zhang T, Kim P, Alber T . A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science. 1993; 262(5138):1401-7. DOI: 10.1126/science.8248779. View

3.
Cox M . Progress on baculovirus-derived influenza vaccines. Curr Opin Mol Ther. 2008; 10(1):56-61. View

4.
Sylte M, Suarez D . Influenza neuraminidase as a vaccine antigen. Curr Top Microbiol Immunol. 2009; 333:227-41. DOI: 10.1007/978-3-540-92165-3_12. View

5.
Li W, Moore M, Vasilieva N, Sui J, Wong S, Berne M . Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426(6965):450-4. PMC: 7095016. DOI: 10.1038/nature02145. View